Cipla says USFDA issued 7 observations after inspecting Bengaluru API unit
The United States Food and Drug Administration (USFDA) issued seven observations after conducting a routine cGMP inspection at Ciplas API manufacturing facility in Virgonangar, Bengaluru, the homegrown pharma major said Friday. The inspection was conducted from June 15 to June 19, Cipla said in a regulatory filing. "The inspection ended with seven observations, none of which were repeat or related to data integrity," Cipla said. The company will respond to the agency within the stipulated timeline, it added.
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
